Tuesday, March 31, 2009
Monday, March 30, 2009
Read more here.
Daniel Carlat comments on the report here.
Sunday, March 29, 2009
Saturday, March 28, 2009
And the article "High cost of malpractice insurance threatens supply of ob/gyns, especially in some urban area" is here.
Friday, March 27, 2009
"A three-legged dog named Trooper overseeing experiments on humans? An ethics committee named “Phaké Medical Devices” and based in “Paynesville, South Carolina”? No problem, sign right up. It was a sting operation tailor-made for congressional theatrics, and the US House of Representatives Committee on Energy and Commerce obliged yesterday as they heard accounts of an undercover operation to expose weaknesses in the country’s fragmented system of human research oversight."
Thursday, March 26, 2009
"The Government Accountability Office also said it was able to register with the Health and Human Services Department a fictitious institutional review board, a panel of doctors and scientists that must approve any medical drug or device to be used in federally funded testing on humans. The president of this fake review board was a dog named Trooper."
Wednesday, March 25, 2009
Monday, March 23, 2009
According to the Wall Street Journal: "The Journal of the American Medical Association, one of the world's most influential medical journals, says it is instituting a new policy for how it handles complaints about study authors who fail to disclose they have received payments from drug companies or others that pose a conflict: It will instruct anyone filing a complaint to remain silent about the allegation until the journal investigates the charge.""The unusual order drew criticism from editors at other journals and fuels a debate about the role of medical journals in policing financial conflicts of researchers."
The WSJ Health Blog also reports on the new policy.
Friday, March 20, 2009
In a contentious Feb. 26 deposition between Dr. Biederman and lawyers for the states, he was asked what rank he held at Harvard. “Full professor,” he answered.
“What’s after that?” asked a lawyer, Fletch Trammell.
“God,” Dr. Biederman responded.
“Did you say God?” Mr. Trammell asked.
“Yeah,” Dr. Biederman said.
Read more in the New York Times about Dr. Joseph Biederman's testimony in a series of lawsuits filed by state attorneys general claiming that makers of antipsychotic drugs defrauded state Medicaid programs by improperly marketing their medicines.
Thursday, March 19, 2009
Wednesday, March 18, 2009
"In the spring of 2000, Dr. S. Charles Schulz attended a national medical conference to present favorable research on a new psychiatric drug called Seroquel. Schulz, chief of psychiatry at the University of Minnesota, reported that the drug was 'significantly superior' to the old gold-standard treatment for schizophrenia. In a press release by the manufacturer, AstraZeneca, he touted the 'dramatic benefits' of Seroquel's class of drugs."
"But newly released documents show that AstraZeneca knew the research didn't support the claim -- and knew two months before Schulz went public with it."In a longer, more detailed story, The Pioneer Press reports that "a U spokesman said that the dean of the medical school, Dr. Deborah Powell, is aware of the controversy over Schulz's research and has offered him her full support. "
PharmaGossip comments here.
Meanwhile, in an AHC News Capsule, AHC VP Frank Cerra comments on financial conflicts of interest:
"I’d like to make a couple of points loud and clear, as I have publicly on several occasions. Yes, the faculty within the Academic Health Center – and indeed in other parts of the University – have relationships with industry. Our new ideas, our discoveries would never go anywhere if there weren’t a company willing to develop or manufacture the results of our work. And then those discoveries would never make it into the marketplace to both improve and enhance care and health. Yes, pharmaceutical and device manufacturers pay for clinical trial work taking place at the University. There is no other source of funds. And, yes, our faculty – physicians, pharmacists, dentists and others – are compensated for their time and work."
"As a result, newly unearthed documents show, Study 15 suffered the same fate as many industry-sponsored trials that yield data drugmakers don't like: It got buried. It took eight years before a taxpayer-funded study rediscovered what Study 15 had found -- and raised serious concerns about an entire new class of expensive drugs."
Tuesday, March 17, 2009
Saturday, March 14, 2009
Friday, March 13, 2009
Thursday, March 12, 2009
Lederer is the Robert Turell Professor of History of Medicine and Bioethics at the University of Wisconsin School of Medicine and Public Health and Chair of the Department of Medical History and Bioethics. She has published extensively on the history of both human and animal experimentation. Her expertise on the history of American medical research prompted her appointment by President Clinton to the Advisory Committee on Human Radiation Experiments.
The Premack judges wrote: “Through the eyes of one patient, this story shed considerable light on the complicated and competing interests between the development and path to market of new drugs, funding needs of the University and the integrity of medical research. The judges are hopeful that the new ethics task force implemented at the U of M is resulting in changes in conflict of interest policies.”
Winners will be honored at the Frank Premack Public Affairs Journalism Awards Program, held Monday, April 20, 2009 at 5:00 p.m. in the A.I. Johnson Room at McNamara Alumni Center.
Read the press release here.
Wednesday, March 11, 2009
Monday, March 09, 2009
Update: the deal is done, for $41.1 billion. The New York Times reports.
Sunday, March 08, 2009
Saturday, March 07, 2009
Friday, March 06, 2009
"Federal prosecutors say that a Massachusetts General Hospital psychiatrist became a 'star spokesman' in helping a pharmaceutical company promote its drugs for treating depressed children, even though the medications were not approved for pediatric use by the US Food and Drug Administration.""In a complaint unsealed last week in US District Court in Boston, prosecutors allege that New York-based
Read more in the Boston Globe.
Thursday, March 05, 2009
Wednesday, March 04, 2009
The 13-page draft banned gifts to faculty, researchers and students from drug and medical device companies. It barred the companies from funding continuing education. It established strict guidelines for reporting industry relationships, including disclosure to patients and the public.
But six months later, a slimmed-down, two-page version bearing a few notable changes is winding its way through the university's considerable bureaucracy toward approval by the Board of Regents." Read more from the Star Tribune.
Tuesday, March 03, 2009
Monday, March 02, 2009
"In a first-year pharmacology class at Harvard Medical School, Matt Zerden grew wary as the professor promoted the benefits of cholesterol drugs and seemed to belittle a student who asked about side effects. Mr. Zerden later discovered something by searching online that he began sharing with his classmates. The professor was not only a full-time member of the Harvard Medical faculty, but a paid consultant to 10 drug companies, including five makers of cholesterol treatments." Read more in the Times.